Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, localized prostate cancerRecently announced positive final data from randomized controlled phase 2a clinical trial of CAN-2409 in borderline resectable pancreatic ductal adenocarcinomaOn track to report biomarker and final overall survival data from open label phase 2a clinical trial per protocol analysis in non-small cell lung cancer (NSCLC) patients who received two ...